Premium
Mycophenolate mofetil in pediatric renal transplantation: A single center experience
Author(s) -
Raheem Omer A.,
Kamel Mohamed H.,
Daly Padraiq J.,
Mohan Ponnusamy,
Little Dilly M.,
Awan Atif,
Hickey David P.
Publication year - 2011
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/j.1399-3046.2009.01179.x
Subject(s) - medicine , transplantation , mycophenolic acid , single center , mycophenolate , regimen , immunosuppression , incidence (geometry) , kidney transplantation , surgery , population , urology , pediatrics , physics , optics , environmental health
Raheem OA, Kamel MH, Daly PJ, Mohan P, Little DM, Awan A, Hickey DP. Mycophenolate mofetil in pediatric renal transplantation: A single center experience.
Pediatr Transplantation 2011: 15:240–244. © 2009 John Wiley & Sons A/S. Abstract: We assessed our long‐term experience with regards to the safety and efficacy of MMF in our pediatric renal transplant population and compared it retrospectively to our previous non‐MMF immunosuppressive regimen. Forty‐seven pediatric renal transplants received MMF as part of their immunosuppressive protocol in the period from January 1997 till October 2006 (MMF group). A previously reported non‐MMF group of 59 pediatric renal transplants was included for comparative analysis (non‐MMF group). The MMF group comprised 29 boys and 18 girls, whereas the non‐MMF group comprised 34 boys and 25 girls. Mean age was 11.7 and 12 yr in the MMF and non‐MMF groups, respectively. The incidence of acute rejection episodes was 11 (23.4%) and 14 (24%) in the MMF and non‐MMF group, respectively. Two (3.3%) grafts were lost in the non‐MMF group compared with one (2.1%) in the MMF group. Twenty‐one (44.68%) patients in the MMF group developed post‐transplant infections compared with 12 (20.33%) in the non‐MMF group (p < 0.0001). In conclusion, the use of MMF in pediatric renal transplantation was not associated with a lower rejection rate or immunological graft loss. It did, however, result in a significantly higher rate of viral infections.